Keystone Symposia

Fairmont Banff Springs Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2020



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Cancer Evolution and Combinatorial Cancer Therapies: Concepts and Challenges (L1)


Organizer(s) William Sellers, Charles Swanton and Lillian Siu
January 19—23, 2020
Fairmont Banff Springs • Banff, AB Canada
Discounted Abstract Deadline: Sep 25, 2019
Abstract Deadline: Oct 17, 2019
Scholarship Deadline: Sep 25, 2019
Discounted Registration Deadline: Nov 20, 2019

Sponsored by BioLegend, Inc., Incyte Corporation, Merck & Co., Inc., Novartis Institutes for BioMedical Research and Roche

Summary of Meeting:
Progress in understanding the clonal and sub-clonal processes driving tumor evolution, tumor heterogeneity, the mechanisms of therapeutic resistance, and in defining new cancer dependencies have converged to help inform more rational approaches to achieving the development of transformative combination therapeutic regimens in cancer. Nonetheless, examples of highly effective rationally elucidated combinations remain rare and the pre-clinical and clinical development challenges to this goal are substantial. As an example, the emergent role of immunotherapeutics having curative potential has led to tremendous excitement, yet increased complexity. The broad swath of empiric based clinical trials attests to the continued and growing need for improved pre-clinical means by which transformative combinations can be identified. This conference will bring together evolutionary and computational biologists, experts in functional genomics, translational scientists, drug discovery researchers and physician leaders in clinical development. The conference program begins with how evolutionary processes drive the “natural” progression of cancer and how such processes lead to the measured heterogeneous populations of cells resident in all tumors. These two related forces, driven at least in part by ongoing mutational processes, then combine to give rise to therapeutic resistance, which enables researchers to robustly identify mechanisms relevant to humans in pre-clinical models. The deeper understanding of these forces can inform specific combination therapeutics, but combination hypotheses are now being discovered though genome-scale functional screening approaches (e.g. CRISPR, shRNA). Speakers have been invited to discuss the studies which are now taking place in both the targeted and immuno-oncology (I/O) therapeutic fields. These talks filter into sessions on understanding how I/O and targeted therapeutics are similar or distinct and to seek the lessons from the clinical trial outputs in the I/O field that will emerge over the next year. Finally, clinical development paradigms for more rapidly testing and developing combinations will be covered during the conference.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, January 19 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, January 23 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, January 24 in order to fully experience the meeting.

SUNDAY, JANUARY 19

16:00—20:00
Arrival and Registration

Riverview Lounge
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Riverview Lounge

MONDAY, JANUARY 20

07:00—08:00
Breakfast

Alberta/New Brunswick
08:00—09:00
Welcome and Keynote Address

Cascade Ballroom
* William R. Sellers, Broad Institute of MIT and Harvard, USA

Charles Swanton, Francis Crick Institute, UK
Cancer Evolution and Immune Escape: TRACERx

09:00—11:30
The Evolution of Cancer I

Cascade Ballroom
* Jens Lagergren, KTH Royal Institute of Technology, Sweden

Carlo Maley, Arizona State University, USA
Lessons in Cancer Prevention from Whales and Other Animals

Coffee Break

Trevor A. Graham, Queen Mary University of London, UK
Evolution of Copy Number Alterations in Colon Cancer

Natalie Andersson, Lund University, Sweden
Short Talk: High-Risk Pediatric Cancer Genomes are Shaped by Intense Phylogenetic Branching Emerging at Specific Points in Evolutionary History

Floris P. Barthel, The Jackson Laboratory, USA
Short Talk: Longitudinal Molecular Trajectories of Diffuse Glioma in Adults

11:30—17:00
On Own for Lunch

11:30—13:00
Poster Setup

Alberta/New Brunswick
13:00—22:00
Poster Viewing

Alberta/New Brunswick
14:30—16:30
Career Roundtable
Interested participants must sign up at the registration desk on a first-come, first-serve basis. Maximum attendance: 60.

New Brunswick
Sohrab Shah, Memorial Sloan Kettering Cancer Center, USA

Jeffrey A. Engelman, Novartis Institutes for BioMedical Research, USA

Amanda Magara, American Association for Cancer Research, USA

Tatiana Prowell, U.S. FDA and Johns Hopkins University, USA

16:30—17:00
Coffee Available

Riverview Lounge
17:00—19:00
The Evolution of Cancer II

Cascade Ballroom
* Lisa Tucker-Kellogg, Duke-NUS Medical School Singapore, Singapore

Andrea Sottoriva, Institute of Cancer Research, UK
Harnessing Evolutionary Steering in Cancer Therapy to Control Drug Resistance

Giovanni Ciriello, University of Lausanne, Switzerland
Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies

Christina Curtis, Stanford University, USA
Quantifying Clonal Evolution Through Treatment and Metastasis

Sarah J. Aitken, University of Cambridge, UK
Short Talk: Pervasive Segregation of DNA Lesions Generates Genetic Diversity in Cancer

James R. Torpy, Garvan Institute of Medical Research, Australia
Short Talk: Copy Number Variation Profiles Derived from Single Cell RNA-Sequencing Data Reveals Diverse Intra-Tumour Heterogeneity across Multiple Breast Cancer Subtypes

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Alberta/New Brunswick
19:30—22:00
Poster Session 1

Alberta/New Brunswick

TUESDAY, JANUARY 21

07:00—08:00
Breakfast

Alberta/New Brunswick
08:00—11:15
Cancer Heterogeneity

Cascade Ballroom
* Karin Jirström, Lund University, Sweden

Sorana Morrissy, University of Calgary, Canada
Tracking Intra-Tumor Heterogeneity in Brain Tumors

Jeffrey A. Engelman, Novartis Institutes for BioMedical Research, USA
The Therapeutic Implications for Cancer Heterogeneity

Coffee Break

Sohrab Shah, Memorial Sloan Kettering Cancer Center, USA
Clonal Genotype and Population Structure Inference from Single-Cell Tumor Sequencing

Thomas G. Graeber, University of California, Los Angeles, USA
Pan-Cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies

Anneleen Daemen, ORIC Pharmaceuticals, USA
Short Talk: Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Therapeutic Vulnerabilities in Lung Cancer

David Gisselsson Nord, Lund University, Sweden
Short Talk: Clonal Dynamics Under Therapy in Neuroblastoma

Hunter Shain, University of California, San Francisco, USA
Short Talk: The Genetic Evolution of Metastatic Uveal Melanoma

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Alberta/New Brunswick
13:00—22:00
Poster Viewing

Alberta/New Brunswick
16:30—17:00
Coffee Available

Riverview Lounge
17:00—19:00
Understanding Checkpoints and Resistance in Immuno-Oncology

Cascade Ballroom
* Anna Vilgelm, Ohio State University, USA

Marios Giannakis, Dana-Farber Cancer Institute, USA
Identification of Modulators of Immune Response from the Clinic: Implications for Combining I/O Agents

Elisabeth G.E. de Vries, Universitair Medisch Centrum Groningen, Netherlands
Molecular Imaging for Immunotherapy

Ashley DiMarco, Duke University, USA
Short Talk: APOBEC Mutagenesis as a Driver of Tumor Evolution through Tumor Cell-Intrinsic Mechanisms and by Modulating Tumor-Immune System Interactions

Fernando Souza-Fonseca-Guimaraes, University of Queensland, Australia
Short Talk: Therapeutic Blockade of TGF-β Superfamily Members Improves NK Cell Function and Anti-Tumor Immunity

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Alberta/New Brunswick
19:30—22:00
Poster Session 2

Alberta/New Brunswick

WEDNESDAY, JANUARY 22

07:00—08:00
Breakfast

Alberta/New Brunswick
08:00—11:00
Leveraging Therapeutic Resistance towards Combination Therapies

Cascade Ballroom
* Darrin D. Stuart, Novartis, USA

Poulikos I. Poulikakos, Icahn School of Medicine at Mount Sinai, USA
Adaptive Resistance Mechanisms and Next Generation Therapeutic Strategies for MAPK-Driven Cancers

Gaddy Getz, Broad Institute, USA
The Elucidation of Drivers of Therapeutic Resistant from Large-Scale Patient Sample Analysis

Coffee Break

Aaron N. Hata, Massachusetts General Hospital, USA
Evolution of Acquired Resistance to Targeted Therapies for Lung Cancer

Himisha Beltran, Dana Farber Cancer Institute, USA
Lineage Plasticity and the Neuroendocrine Phenotype as a Resistance Mechanism in Prostate Cancer

Matthew J. Martin, AstraZeneca, UK
Short Talk: Eliminating Osimertinib Drug Tolerant Persister Cells Via Activation of the Extrinsic Apoptosis Pathway

Sean Misek, Michigan State University, USA
Short Talk: Identification of Pharmacological Vulnerabilities in BRAFi-Resistant Melanoma

11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Alberta/New Brunswick
13:00—22:00
Poster Viewing

Alberta/New Brunswick
16:30—17:00
Coffee Available

Riverview Lounge
17:00—19:00
The Preclinical Modeling and Discovery of Combinations

Cascade Ballroom
* Dieter Saur, Technical University Munich, Germany

William R. Sellers, Broad Institute of MIT and Harvard, USA
Targeting Genetic Redundancy in Cancer through Combinatorial CRISPR Screens

Jonathan S. Weissman, University of California, San Francisco, USA
Single-Cell-Resolution Lineage Tracing of Tumors in a Mouse Xenograft Model Reveals Rapid and Multidirectional Metastasis

Peter Sorger, Harvard Medical School, USA
Adaptation of BRAF-Mutant Melanoma Cells to RAF/MEK Inhibitors and Subsequent Progression to Drug Resistance

Kasey L. Couts, University of Colorado Denver, USA
Short Talk: Loss of Innate Immune Sensing Contributes to Mucosal Melanoma Development and Immunotherapy Resistance

Sophia Wild, University of Cambridge, UK
Short Talk: ClonEx-Seq: Characterising Clonal Evolution in Time and Space with a Toolkit of Expressable Barcodes

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Alberta/New Brunswick
19:30—22:00
Poster Session 3

Alberta/New Brunswick

THURSDAY, JANUARY 23

07:00—08:00
Breakfast

Alberta/New Brunswick
08:00—11:00
Therapeutic Combinations

Cascade Ballroom
* Hunter Shain, University of California, San Francisco, USA

Lillian L. Siu, Princess Margaret Hospital, Canada
Oncology Drug Combinations - Are We at an Impasse?

Steven Stein, Incyte, USA
The Development of IO Combinations

Coffee Break

Shumei Kato, University of California, San Diego Moores Cancer Center, USA
N-of-1 Biomarker-Based Customized Combination Therapy: The PREDICT Family of Studies

Akash Mitra, University of Texas MD Anderson Cancer Center, USA
Short Talk: Immune Enrichment and T-Cell Receptor (TCR) Frequencies Predict Response to Immune Checkpoint Blockade (ICB) in Sarcoma

Anna Vilgelm, Ohio State University, USA
Short Talk: Combination Treatment with MDM2 Antagonist Overcomes Intrinsic Resistance to CDK4/6 Inhibition

11:00—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Riverview Lounge
17:00—18:45
Clinical Trials and Clinical Trial Design

Cascade Ballroom
* Viola Chen, Merck, USA

Tatiana Prowell, U.S. FDA and Johns Hopkins University, USA
The Regulatory View on the Development of Combination Therapeutics

Jeanne Tie, Peter MacCallum Cancer Centre / Walter & Eliza Hall Institute, Australia
Can Circulating Tumor DNA Re-Define the Adjuvant Treatment Paradigm?

Antoni Ribas, University of California, Los Angeles, USA
Testing I/O Combinations in Clinical Trials

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Cascade Ballroom
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Alberta/New Brunswick
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Alberta/New Brunswick

FRIDAY, JANUARY 24

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:

BioLegend, Inc. Incyte Corporation
Merck & Co., Inc. Novartis Institutes for BioMedical Research
Roche
 

We gratefully acknowledge additional support from these exhibitors at this conference:

American Association for Cancer Research (AACR) Myriad-RBM
Please stop by to meet these exhibitors during the conference.


We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13CA246935-01

Funding for this conference was made possible (in part) by 1R13CA246935-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Incyte Corporation


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179